Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
@article{Kerlan2013UseOI, title={Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.}, author={V. Kerlan and D. Gouet and M. Marre and {\'E}. Renard}, journal={Annales d'endocrinologie}, year={2013}, volume={74 5-6}, pages={ 487-90 } }
Insulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42 hours. Two clinical trials comparing insulin degludec and insulin glargine in basal-bolus therapy have recently been published. Both were 52-week, multicentre, randomised (3:1), treat-to-target trials in patients already using insulin. In both type 1 (n=629) and type 2 diabetes (n=1006), insulin degludec was non-inferior… CONTINUE READING
Tables and Topics from this paper
Tables
2 Citations
References
SHOWING 1-10 OF 18 REFERENCES
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- Medicine
- The Lancet
- 2012
- 320
- PDF
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- Medicine
- The Lancet
- 2012
- 274
- Highly Influential
- PDF
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
- Medicine
- Diabetes Care
- 2012
- 272
- PDF
A review of human and analogue insulin trials.
- Medicine
- Diabetes research and clinical practice
- 2007
- 119
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- Biology, Medicine
- Pharmaceutical Research
- 2012
- 310
- PDF
Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes
- Medicine
- Current medical research and opinion
- 2005
- 192
Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs
- Medicine
- Journal of medical economics
- 2011
- 149
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Medicine
- Diabetologia
- 2012
- 2,867
- PDF
The impact of non-severe hypoglycemic events on work productivity and diabetes management.
- Medicine
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
- 2011
- 229